WO2013013165A3 - Use of lna compounds for therapeutic inhibition of mir-21 in systemic lupus erythematosus - Google Patents
Use of lna compounds for therapeutic inhibition of mir-21 in systemic lupus erythematosus Download PDFInfo
- Publication number
- WO2013013165A3 WO2013013165A3 PCT/US2012/047638 US2012047638W WO2013013165A3 WO 2013013165 A3 WO2013013165 A3 WO 2013013165A3 US 2012047638 W US2012047638 W US 2012047638W WO 2013013165 A3 WO2013013165 A3 WO 2013013165A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mir
- lupus erythematosus
- systemic lupus
- therapeutic inhibition
- lna compounds
- Prior art date
Links
- 108091062762 miR-21 stem-loop Proteins 0.000 title abstract 3
- 108091041631 miR-21-1 stem-loop Proteins 0.000 title abstract 3
- 108091044442 miR-21-2 stem-loop Proteins 0.000 title abstract 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention encompasses compositions of LNA antimiRs as well as methods of their use for the regulation of miR-21 expression. The present invention encompasses methods of treating diseases where miR-21 is up-regulated. An example of such a disease is Systemic Lupus Erythematosus (SLE).
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161510283P | 2011-07-21 | 2011-07-21 | |
US61/510,283 | 2011-07-21 | ||
US201161511854P | 2011-07-26 | 2011-07-26 | |
US61/511,854 | 2011-07-26 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2013013165A2 WO2013013165A2 (en) | 2013-01-24 |
WO2013013165A3 true WO2013013165A3 (en) | 2013-04-11 |
Family
ID=47558744
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2012/047638 WO2013013165A2 (en) | 2011-07-21 | 2012-07-20 | Use of lna compounds for therapeutic inhibition of mir-21 in systemic lupus erythematosus |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2013013165A2 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9181547B2 (en) | 2011-04-25 | 2015-11-10 | Regulus Therapeutics Inc. | MicroRNA compounds and methods for modulating MIR-21 activity |
PL398796A1 (en) * | 2012-04-11 | 2013-10-14 | Krzysztof Selmaj | The use of miRNA molecules and antagomir for miRNA in the diagnosis, prevention and treatment of multiple sclerosis |
SG11201406931XA (en) | 2012-04-25 | 2014-11-27 | Regulus Therapeutics Inc | Microrna compounds and methods for modulating mir-21 activity |
UA116639C2 (en) | 2012-10-09 | 2018-04-25 | Рег'Юлес Терап'Ютікс Інк. | Methods for treatment of alport syndrome |
JOP20200228A1 (en) | 2015-12-21 | 2017-06-16 | Novartis Ag | Compositions and methods for decreasing tau expression |
US12016314B2 (en) | 2017-09-08 | 2024-06-25 | Ohio State Innovation Foundation | MicroRNA inhibitor therapy in systemic lupus erythematosus |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100286234A1 (en) * | 2006-04-03 | 2010-11-11 | Joacim Elmen | Pharmaceutical Composition Comprising Anti-Mirna Antisense Oligonucleotides |
US20100298410A1 (en) * | 2007-10-04 | 2010-11-25 | Santaris Pharma A/S | MICROMIRs |
US20100322909A1 (en) * | 2009-06-17 | 2010-12-23 | The University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Th1-associated micrornas and their use for tumor immunotherapy |
US20110118339A1 (en) * | 2008-01-18 | 2011-05-19 | Alnylam Pharmaceuticals, Inc. | Chemically modified oligonucleotides and uses thereof |
-
2012
- 2012-07-20 WO PCT/US2012/047638 patent/WO2013013165A2/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100286234A1 (en) * | 2006-04-03 | 2010-11-11 | Joacim Elmen | Pharmaceutical Composition Comprising Anti-Mirna Antisense Oligonucleotides |
US20100298410A1 (en) * | 2007-10-04 | 2010-11-25 | Santaris Pharma A/S | MICROMIRs |
US20110118339A1 (en) * | 2008-01-18 | 2011-05-19 | Alnylam Pharmaceuticals, Inc. | Chemically modified oligonucleotides and uses thereof |
US20100322909A1 (en) * | 2009-06-17 | 2010-12-23 | The University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Th1-associated micrornas and their use for tumor immunotherapy |
Non-Patent Citations (6)
Title |
---|
FLUITER ET AL.: "Filling the gap in LNA antisense oligo gapmers: the effects of unlocked nucleic acid (UNA) and 4'-C-hydroxymethyl-DNA modifications on RNase H recruitment and efficacy of an LNA gapmer.", MOL. BIOSYST., vol. 5, no. 8, 2009, pages 838 - 843 * |
GARCHOW ET AL.: "Silencing of microRNA-21 in vivo ameliorates autoimmune splenomegaly in lupus mice.", EMBO MOL MED., vol. 3, no. 10, 1 September 2011 (2011-09-01), pages 605 - 615 * |
OBAD ET AL.: "Silencing of microRNA families by seed-targeting tiny LNAs.", NAT GENET., vol. 43, no. 4, 20 March 2011 (2011-03-20), pages 371 - 378 * |
QIAGEN.: "hsa-mir-21", 2008, Retrieved from the Internet <URL:https://www.qiagen.com/geneglobe/miprimerview.aspx?keepresult=true&producttype=88ID=MS00009086#ProductList> [retrieved on 20121217] * |
ROSSI.: "Stopping RNA interference at the seed.", NAT GENET., vol. 43, no. 4, 29 March 2011 (2011-03-29), pages 288 - 289 * |
STAGAKIS ET AL.: "Identification of novel microRNA signatures linked to human lupus disease activity and pathogenesis: miR-21 regulates aberrant T cell responses through regulation of PDCD4 expression.", ANN RHEUM DIS., vol. 70, no. 8, 20 May 2011 (2011-05-20), pages 1496 - 1506 * |
Also Published As
Publication number | Publication date |
---|---|
WO2013013165A2 (en) | 2013-01-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL263843B (en) | Antisense compounds containing an antisense oligonucleotide complementary to nucleic acid transcription and compositions containing them for the treatment of related metabolic diseases | |
WO2013134336A3 (en) | Inhibition of adaptor associated kinase 1 for the treatment of pain | |
MX339873B (en) | Serine/threonine kinase inhibitors. | |
CL2015001442A1 (en) | Method for treating lung diseases comprising the use of compounds derived from obetolic acid. | |
WO2013181579A3 (en) | Tetrahydropyrazolopyrimidine compounds | |
WO2013013165A3 (en) | Use of lna compounds for therapeutic inhibition of mir-21 in systemic lupus erythematosus | |
EP2768525A4 (en) | FORMANTS OF STERILE STABILIZED BY METALLIC IONS | |
WO2012020307A3 (en) | Therapeutic uses of microvesicles and related micrornas | |
PT2925757T (en) | Compounds and compositions for the treatment of parasitic diseases | |
GEP20186864B (en) | Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders | |
WO2012173682A3 (en) | Compounds and methods for the treatment of isocitrate dehydrognase related diseases | |
PH12016501941B1 (en) | Use of heterocyclic compounds for controlling nematodes | |
WO2012136383A8 (en) | Preparation of sitagliptin intermediates | |
EP3087184A4 (en) | Methods and compositions for the specific inhibition of glycolate oxidase (hao1) by double-stranded rna | |
IN2014DN05772A (en) | ||
EP2967049A4 (en) | Methods, compounds, and compositions for the treatment of angiotensin-related diseases | |
WO2012061754A3 (en) | Compounds and methods for treating autoimmune diseases | |
PT2806743T (en) | Antifungal formulations comprising an extract from rheum roots for the treatment of plant diseases | |
WO2012048265A3 (en) | Methods of treating inflammation | |
WO2012104823A3 (en) | Pyridopyrimidinone compounds in the treatment of neurodegenerative diseases | |
EP2994460A4 (en) | Compounds for treatment of angiogenesis-mediated diseases | |
HK1194665A1 (en) | Compositions for the treatment of neurologic disorders | |
WO2012112674A3 (en) | Compounds and methods of use thereof for treating neurodegenerative disorders | |
EP2681207A4 (en) | Heterocyclic compounds for the inhibition of pask | |
PL2552244T3 (en) | Inhibition of undesired sensory effects by the compound camphor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12814291 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 12814291 Country of ref document: EP Kind code of ref document: A2 |